Bricktown Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bricktown Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$284K	Buy	+1,800	New	+$284K	0.05%	30

Other funds holding XBI

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return

Williams Jones Wealth Management New York $8.94B AUM 17.99% 1-Year Est. Return

Annex Advisory Services Brookfield, Wisconsin $6.11B AUM 13.75% 1-Year Est. Return

Bricktown Capital's XBI Position: Q3 2026 in Review

Bricktown Capital opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q3 2026: 1,800 shares worth $284K. The stake represents 0.05% of the portfolio and ranks #30 among its holdings.

522 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

Bricktown Capital held 1,800 shares of State Street SPDR S&P Biotech ETF worth $284K as of Q3 2026.
State Street SPDR S&P Biotech ETF was a new Bricktown Capital position in Q3 2026.
State Street SPDR S&P Biotech ETF made up 0.05% of Bricktown Capital's portfolio in Q3 2026, its #30 holding.
522 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Bricktown Capital's 13F filing for Q3 2026, filed 13 Oct 2026.